BSH 2023 | Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL
Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses a recent publication from his research group on the outcomes of first-line therapy after CD19 CAR-T cell treatment failure in patients with large B-cell lymphoma (LBCL). Dr Shouval explains that, at the time of the study, progression and relapse were common after treatment with CD19 CAR-T cells, yet the reasons for these outcomes were unclear. Dr Shouval outlines risk factors found to be associated with shorter overall survival (OS), but notes that the impacts of specific regimen types could not be compared due to low study power. Results from this study demonstrate the need to explore novel approaches and improve treatment options for this group of patients. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
